The National Institutes of Health (NIH) has awarded $997,068 to a biopharmaceutical company to conduct preclinical research to evaluate the potential of NSI-189, which is a small molecule compound, for the prevention and treatment of diabetic neuropathy.
Other research into NSI-189 conducted by the groups at the University of California, San Diego demonstrated that NSI-189 could prevent and reverse peripheral neuropathy in mice for Type 1 and Type 2 diabetes. The research, led by Dr. Corinne Jolivalt and Dr. Nigel Calcutt, showed that the molecule compound provided significant protection of motor and sensory nerve function in mice with Type 1 diabetes when given from the onset of disease. They also showed improved nerve function when treated two months after the onset of the disease. They found very similar results when testing mice with Type 2 diabetes.
“We look forward to continuing these important studies with UCSD to better understand the potential of NSI-189 in treating diabetic neuropathy,” said Rich Daly, chairman and CEO, Neuralstem. “Diabetic neuropathy is a chronic and debilitating disease that remains an unmet medical need, and we appreciate the NIH’s recognition of the importance of this research.”
“The initial data obtained from our preclinical study with Neuralstem’s compound showed improvement in almost all indices of peripheral neuropathy. This is rather unique, and we look forward to testing NSI-189 in greater depth with this funding,” said Dr. Corinne Jolivalt, the lead collaborator at UCSD where the animal study will take place and with whom the grant money will be shared.